Close

Shire's (SHPG) ONIVYDE Receives EC Marketing Authorization for Treatment of Metastatic Adenocarcinoma of the Pancreas

October 18, 2016 5:59 AM EDT Send to a Friend
Shire plc (Nasdaq: SHPG) announced that the European Commission (EC) has granted Marketing Authorization of ONIVYDE® (pegylated liposomal irinotecan hydrochloride ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login